QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VI Duplicate Management of Suspected Adverse Reaction Reports

Test your understanding of the concepts covered by GVP Module VI: Duplicate Management of Suspected Adverse Reaction Reports.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A branded product appears in one report and only the active substance appears in another. What is the appropriate duplicate-management response?

Treat them as unrelated because the product names are not identical Assess whether the brand and active substance represent the same exposure, together with other matching evidence Merge them automatically because all products with the same active substance are always duplicates Exclude the active-substance report from the safety database

Question 2 of 10 What should happen when a duplicate report contains a laboratory result and outcome information absent from the retained case?

The information should be ignored because the report is a duplicate The information should be assessed and incorporated where relevant, including consideration of its effect on seriousness, outcome, causality, or reportability The duplicate should automatically become the master case The information should be used only for marketing purposes

Question 3 of 10 How should reporter identity generally be used in duplicate assessment?

A shared reporter proves that two reports concern the same patient Different reporters prove that the reports concern different patients Reporter identity is supporting evidence that must be interpreted with other case information Reporter identity should never be considered because it is not clinical information

Question 4 of 10 Which approach provides the strongest basis for duplicate assessment?

Use one highly specific field as a definitive identifier Compare multiple patient, product, event, temporal, reporter, and narrative elements Compare only the coded adverse reaction terms Compare only the case creation dates

Question 5 of 10 Two reports are from the same hospital and involve the same product and common reaction, but they contain different patient identifiers, incompatible event timelines, and distinct clinical narratives. What is the best conclusion?

Confirm duplication because the hospital and product match Retain the cases as separate because the broader evidence supports different patients or episodes Merge the cases and retain only the more serious outcome Mark the cases as confirmed duplicates solely because the reporters work in the same institution

Question 6 of 10 Which principle best defines an ICSR duplicate?

Two reports containing the same adverse reaction term Two reports concerning the same underlying individual case Two reports received through different reporting channels Two reports involving the same medicinal product

Question 7 of 10 Why are different case identifiers not sufficient evidence that two reports concern different patients?

Case identifiers are not required in pharmacovigilance systems Each reporting route or organisation may create its own record for the same underlying case Case identifiers identify medicinal products rather than reports Different identifiers mean that both reports must be merged

Question 8 of 10 Why should clinical narratives be reviewed in difficult duplicate assessments?

Narratives replace the need to compare patient identifiers Narratives may reveal shared admissions, investigations, treatment sequences, or distinctive events not captured in coded fields Narratives are legally more authoritative than all structured data Narratives are used only to determine reporter qualification

Question 9 of 10 A sudden increase in confirmed duplicates from one affiliate is observed. What is the most appropriate interpretation?

It necessarily demonstrates a new product safety signal It may indicate a workflow, interface, or reporting-process change rather than a change in the underlying safety profile It proves that all affiliate reports should be suppressed It demonstrates that the duplicate algorithm is fully reliable

Question 10 of 10 How should duplicate review be prioritised in a risk-based process?

Every candidate pair must receive exactly the same level of investigation Only reports with identical structured fields should be reviewed Distinctive or clinically important potential matches should be escalated appropriately, while low-information similarities may require proportionate assessment Only non-serious reports should be reviewed because serious reports are already controlled

Knowledge Assessment: GVP Module VI Duplicate Management of Suspected Adverse Reaction Reports

Cookie Settings